If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
<br /> A SUPPLEMENT TO NEUROLOGY REVIEWS<br /> <br /> Clinical Reviews of JCV and PML<br /> JULY 2011<br /> <br /> <br /> Understanding the Complexities of<br /> JCV and PML<br /> <br /> An Overview of<br /> JC Virus and<br /> Progressive Multifocal<br /> Leukoencephalopathy<br /> <br /> <br /> <br /> The Epidemiology of<br /> Progressive Multifocal<br /> Leukoencephalopathy<br /> <br /> <br /> <br /> Progressive Multifocal<br /> Leukoencephalopathy:<br /> Survival Statistics<br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> Supported by Biogen Idec<br /> Understanding the<br /> Complexities of<br /> JCV and PML<br
A SUPPLEMENT TO NEUROLOGY REVIEWSClinical Rev
A SUPPLEMENT TO NEUROLOGY REVIEWSClinical Rev
Understanding theComplexities ofJCV and PML
Understanding theComplexities ofJCV and PML
An Overview of JC Virusand Progressive Multifoca
An Overview of JC Virusand Progressive Multifoca
rus of the genus Papovaviridae that was firstiso
rus of the genus Papovaviridae that was firstiso
cation. Although PML is generally consideredto b
cation. Although PML is generally consideredto b
VP1 capsid protein are associated with the de-ve
VP1 capsid protein are associated with the de-ve
JCV exposure than those who are not immu-nocompe
JCV exposure than those who are not immu-nocompe
References1. Tan CS, Koralnik IJ. Progressi
References1. Tan CS, Koralnik IJ. Progressi
39. Weber F, Goldmann C, Krämer M, et al. Ce
39. Weber F, Goldmann C, Krämer M, et al. Ce
The Epidemiologyof Progressive MultifocalLeukoe
The Epidemiologyof Progressive MultifocalLeukoe
ticularly oligodendrocytes. PML is now knownto b
ticularly oligodendrocytes. PML is now knownto b
diseases, which represent an autoimmune in-
diseases, which represent an autoimmune in-
tive therapies appear to exert some change onthe
tive therapies appear to exert some change onthe
tainment of JCV in the CNS as well as influ-ence
tainment of JCV in the CNS as well as influ-ence
For example, CSF assays of JCV DNA have cor-rela
For example, CSF assays of JCV DNA have cor-rela
10. Chapagain ML, Nerurkar VR. Human poly
10. Chapagain ML, Nerurkar VR. Human poly
Progressive MultifocalLeukoencephalopathy:Survi
Progressive MultifocalLeukoencephalopathy:Survi
TABLE 1 Common clinical features of AIDS-associa
TABLE 1 Common clinical features of AIDS-associa
TABLE 2 Different forms of PML Classic PMLPML
TABLE 2 Different forms of PML Classic PMLPML
TABLE 3 Summary of agents predisposing to PMLAg
TABLE 3 Summary of agents predisposing to PMLAg
characteristic brain changes on magnetic res-ona
characteristic brain changes on magnetic res-ona
88% (22 of 25) sera from natalizumab-associ-ated
88% (22 of 25) sera from natalizumab-associ-ated
with HIV-associated PML, recent studies sug-gest
with HIV-associated PML, recent studies sug-gest
The marked difference in survival in thatmul
The marked difference in survival in thatmul
Natalizumab, the first monoclonal anti-bo
Natalizumab, the first monoclonal anti-bo
was employed, the patient developed PMLseve
was employed, the patient developed PMLseve
22. Lebwohl M, Tyring SK, Hamilton TK, et al.
22. Lebwohl M, Tyring SK, Hamilton TK, et al.